摘要
目的评价降纤酶治疗急性进展型脑梗死的临床效果及其安全性。方法60例脑梗死患者被随即分为两组,治疗组30例,对照组30例。分别对治疗组和对照组进行动态疗效判定和实验室指标对比。结果2周后,治疗组BI总分改善情况明显优于对照组(P<0.05),且治疗总有效率分别为90.0%和46.7%,治疗组优于对照组(P<0.05)。治疗组血浆纤维蛋白原水平降低显著。结论降纤酶治疗急性进展性脑梗死疗效、安全性较好。
Objective To evaluate the clinical effects and safety of defibrase on acute cerebral infarction. Methods 60 patients with acute cerebral infarction were randomly divided into two groups, each group consisted of thirty cases. Assessment on dynamic curative effect and contrast on laboratory index were respectively applied in two groups, Results After two weeks, therapeutic groups were better than control groups on the improve of BI （P 〈 0.05 ）, total effective rate of two groups were 90% and 46.67% respectively, therapeutic groups were better than control groups （P 〈 0.05 ）, and plasma fibrinogen were remarkably cut down in therapeutic groups （ P 〈 0.05 ）. Conclusions Defibrase is effective and safety on acute cerebral infarction.
出处
《实用全科医学》
2007年第3期217-218,共2页
Applied Journal Of General Practice
关键词
降纤酶
脑梗死
神经功能
Defibrase
Cerebral infarction
Nerve function
